Notably, defined PD-L1 cutoffs based on different interpretations (e.g., combined positive score [CPS] ≥ 1, tumor proportion score [TPS] ≥ 1%) have been approved by the US Food and Drug Administration to guide the selection of patients to receive anti-PD-1 (e.g., nivolumab and pembrolizumab) or anti-PD-L1 antibodies [43–45]. This evidence concerns the gene CD274 and neoplasm.